Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.
Miyauchi E, Morita S, Nakamura A, Hosomi Y, Watanabe K, Ikeda S, Seike M, Fujita Y, Minato K, Ko R, Harada T, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Miyauchi E, et al. Among authors: minato k. J Clin Oncol. 2022 Nov 1;40(31):3587-3592. doi: 10.1200/JCO.21.02911. Epub 2022 Aug 12. J Clin Oncol. 2022. PMID: 35960896 Free PMC article. Clinical Trial.
Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations.
Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T. Oizumi S, et al. Among authors: minato k. ESMO Open. 2018 Feb 23;3(2):e000313. doi: 10.1136/esmoopen-2017-000313. eCollection 2018. ESMO Open. 2018. PMID: 29531840 Free PMC article.
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Hosomi Y, et al. Among authors: minato k. J Clin Oncol. 2020 Jan 10;38(2):115-123. doi: 10.1200/JCO.19.01488. Epub 2019 Nov 4. J Clin Oncol. 2020. PMID: 31682542 Clinical Trial.
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T. Sugawara S, et al. Among authors: minato k. Ann Oncol. 2015 May;26(5):888-894. doi: 10.1093/annonc/mdv063. Epub 2015 Feb 10. Ann Oncol. 2015. PMID: 25669832 Free article. Clinical Trial.
Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809.
Niho S, Ikeda N, Michimae H, Suzuki K, Sakai H, Kaburagi T, Yoshiya K, Minato K, Kato T, Okamoto H, Seto T, Hosomi Y, Shimizu K, Saito H, Tsuchida M, Kunitoh H, Tsuboi M, Takeuchi M, Watanabe K. Niho S, et al. Among authors: minato k. Am J Clin Oncol. 2018 Nov;41(11):1113-1117. doi: 10.1097/COC.0000000000000438. Am J Clin Oncol. 2018. PMID: 29521649
Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.
Hosomi Y, Tanai C, Yoh K, Goto Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H. Hosomi Y, et al. Among authors: minato k. Expert Opin Pharmacother. 2018 Jul;19(10):1049-1056. doi: 10.1080/14656566.2018.1484903. Epub 2018 Jun 21. Expert Opin Pharmacother. 2018. PMID: 29871540
A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101.
Kasai T, Mori K, Kishi K, Kaburagi T, Hosomi Y, Imai H, Yamada Y, Yomota M, Moriguchi S, Seike M, Minato K, Gemma A; Tokyo Cooperative Oncology Group. Kasai T, et al. Among authors: minato k. Int J Clin Oncol. 2020 May;25(5):867-875. doi: 10.1007/s10147-020-01629-6. Epub 2020 Feb 14. Int J Clin Oncol. 2020. PMID: 32060768 Clinical Trial.
Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study.
Goto Y, Tanai C, Yoh K, Hosomi Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H. Goto Y, et al. Among authors: minato k. ESMO Open. 2017 Sep 14;2(4):e000214. doi: 10.1136/esmoopen-2017-000214. eCollection 2017. ESMO Open. 2017. PMID: 29018574 Free PMC article.
Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Miyanaga A, Kubota K, Hosomi Y, Okuma Y, Minato K, Fujimoto S, Okamoto H, Satouchi M, Isobe H, Aono H, Takiguchi Y, Gemma A; Tokyo Cooperative Oncology Group. Miyanaga A, et al. Among authors: minato k. Jpn J Clin Oncol. 2019 Aug 1;49(8):749-754. doi: 10.1093/jjco/hyz064. Jpn J Clin Oncol. 2019. PMID: 31070750 Clinical Trial.
Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017.
Nakahara Y, Hosomi Y, Shibuya M, Mitsufuji H, Katagiri M, Naoki K, Soejima K, Nogami N, Nagase S, Nishikawa M, Minato K, Takiguchi Y, Seki N, Yamada K, Seto T, Okamoto H. Nakahara Y, et al. Among authors: minato k. Mol Clin Oncol. 2019 Oct;11(4):349-353. doi: 10.3892/mco.2019.1903. Epub 2019 Jul 23. Mol Clin Oncol. 2019. PMID: 31475062 Free PMC article.
589 results